Immune Disorder HSCT Protocol

Overview

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

Full Title of Study: “A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2022

Interventions

  • Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    • Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF

Arms, Groups and Cohorts

  • Experimental: Preparative

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with donor engraftment
    • Time Frame: 1 year post transplant

Secondary Measures

  • Major Transplant Related Toxicities
    • Time Frame: 1 years post transplant
  • Time to neutrophil recovery
    • Time Frame: within 100 days post transplant
  • Number of patient with acute GVHD
    • Time Frame: 180 days post transplant
  • Number of participants with infectious complications
    • Time Frame: 2 years post transplant
  • Time to immune reconstitution
    • Time Frame: 2 years post transplant
  • Overall survival
    • Time Frame: 2 years post transplant
  • Time to platelet recovery
    • Time Frame: within 100 days post transplant
  • Number of patients with chronic GVHD
    • Time Frame: 2 years post transplant
  • Disease free survival
    • Time Frame: 2 years post transplant

Participating in This Clinical Trial

Inclusion Criteria

  • </= 21 years of age – Performance status >/= 40 – DLCO >/= 40% – LVEF >/=40% or LVSF >/=26% – Serum creatinine < 2x ULN – Liver enzymes </= 5x ULN – Negative pregnancy test – Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6 matched unrelated UCB, 7-8/8 matched unrelated BM, double cord) Exclusion Criteria:

  • Known diagnosis of HIV I/II – Pregnant or breastfeeding – Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting alemtuzumab – Uncontrolled viral infection within 1 week prior to starting alemtuzumab

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Washington University School of Medicine
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.